论文部分内容阅读
目的：研究 P-糖蛋白 (P- glycoprotein,P- gp)的表达与 bcl- 2蛋白和增殖细胞核抗原 (proliferating- cell nuclear antigen,PCNA)表达的关系及意义。方法：用特异性鼠抗人单克隆抗体，用 SP免疫组织化学方法检测石蜡包埋的肺癌标本中 P- gp， bcl- 2蛋白和 PCNA的表达。结果：在小细胞肺癌（ small cell lung cancer， SCLC）中， P- gp阳性表达者 PCNA标记指数（ labelling index,LI）高于 P- gp阴性者，而 bcl- 2蛋白的表达与 P- gp的表达有关。在非小细胞肺癌（ non- small cell lung cancer， NSCLC）中， bcl- 2蛋白的表达和 PCNA LI均与 P- gp的表达无关。结论：细胞增殖在 SCLC的多药耐药中起了部分作用， bcl- 2凋亡抑制基因与 P- gp间可能存在某种相关性。
Objective: To study the relationship between the expression of P-glycoprotein (P-gp) and the expression of bcl-2 protein and proliferating cell nuclear antigen (PCNA). METHODS: The expression of P-gp, bcl-2 protein and PCNA in paraffin-embedded lung cancer specimens was detected by SP immunohistochemistry with specific mouse anti-human monoclonal antibody. RESULTS: In small cell lung cancer (SCLC), the PCNA labeling index (LI) was higher in P-gp-positive patients than in P-gp-negative patients. The expression of bcl-2 protein and P-gp were detected in SCLC. The expression is relevant. In non-small cell lung cancer (NSCLC), both the expression of bcl-2 protein and PCNA LI were not related to the expression of P-gp. Conclusion: Cell proliferation plays a part in multidrug resistance of SCLC. There may be some correlation between bcl-2 apoptosis-suppressing gene and P-gp.